血清sIL-2R和CA125水平对卵巢恶性肿瘤临床诊断意义的探讨

 分别采用ELISA和RIA对36例卵巢恶性肿瘤、34例妇科良性肿瘤患者及31例正常女性献血员血清可溶性白细胞介素-2受体(sIL－2R)和CA125水平进行检测。结果:术前卵巢恶性肿瘤患者血清SIL－2R和CA125水平均明显高于良性及正常对照组(P<0.01)。血清sIL－2R检测恶性肿瘤的敏感性为77.8％,特异性为76.5％。血清CA125的敏感性为83.3％,特异性为73.5％。其中,对卵巢上皮癌敏感性为90.4％。联合检测卵巢恶性肿瘤患者血清sIL－2R和CA125的敏感性为57.4％,特异性为94.7％。提示:术前单项血清sIL－2R或CA125不能作为诊断和筛选卵巢恶性肿瘤的依据,联合检测血清sIL－2R或CA125可明显提高特异性,降低假阳性率,有助于临床手术方式的制定和以后治疗成功的可能性。

Serum soluble interleukin～2 receptor (sIL～2R) and CA125 assay in ovarian cancer

The levels of serum soluble interleukin～2 receptor (sIL～2R) and CA125 in36 patients with ovarian cancer, 34 ones with benign gynecological tumor and 31 blooddonors were measured by ELISA and RIA,respectively.Compared to those of benign andnormal controls, serum levels of sIL～2R and CA125 in patients with ovarian cancer elevated significantly (P<0.01).Sensitivity and specificity of Serum sIL～2R were 77.8%and 76.5% respectively.Those of CA125 were 83.3% and 73.5%,sensitivity of CA125 forovarian epithelial cancer was 90.4%.Sensitivity and specificity of combination of SerumsIL ～2R and CA125 were 57.4% and 94.7%, respectively.We concluded that serum sIL～2Rand CA125 alone might not be applied to identify and screen for ovarian cancer.Measurement of sll～2R combined with CA125 could significantly increase the specificity anddecrease false positive rate, therefore,it was helpful for the surgeon to draw up the furthertherapeutic program before operation and could raise the possibility of success.